Acrivon Therapeutics, Inc.
ACRV
DELAYED 1 MONTH
28 insider filings · Latest: Jul 21, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | Jul 23 8:28 PM | Mary MillerChief Legal Officer | Sale | 573 | $1.76 | $1.0K | 82,194(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | Mar 3 9:22 PM | Katharine PetersonChief Accounting Officer | Grant/Award | 31,900 | $1.51 | 31,900(D) | View → |
| Mar 1, 2026 | Mar 3 9:21 PM | Mansoor Raza MirzaChief Medical Officer | Grant/Award | 174,068 | $1.51 | 174,068(D) | View → |
| Mar 1, 2026 | Mar 3 9:19 PM | Mary MillerChief Legal Officer | Grant/Award | 129,760 | $1.51 | 129,760(D) | View → |
| Mar 1, 2026 | Mar 3 9:19 PM | Adam D. LevyChief Financial Officer | Grant/Award | 132,925 | $1.51 | 132,925(D) | View → |
| Mar 1, 2026 | Mar 3 9:17 PM | Erick GamelinChief Development Officer | Grant/Award | 94,946 | $1.51 | 94,946(D) | View → |
| Mar 1, 2026 | Mar 3 9:16 PM | Eric DevroeChief Operating Officer | Grant/Award | 186,728 | $1.51 | 186,728(D) | View → |
| Mar 1, 2026 | Mar 3 9:15 PM | Peter Blume-JensenDirector, President and CEO | Grant/Award | 602,705 | $1.51 | 185,495(I) | View → |